Stock Ratings / Health Care / SXTP / options

ONCO (30) GRI (34) EOCN (34) ERNA (33) ⌘ Pro Terminal →

60 Degrees Pharmaceuticals Inc. (SXTP) Options Positioning, Max Pain & Unusual Sweeps

$0.94 -0.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.94

60 Degrees Pharmaceuticals Inc. (SXTP) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SXTP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SXTP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.94 (-0.79% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SXTP ranks #524 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SXTP compare to ONCO and GRI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SXTP carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 22.3%, and ROIC of -35.0%. By comparison, ONCO (Onconetix Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M) and GRI (GRI Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, SXTP leads on earnings multiple (N/A) while SXTP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SXTP?

▼

Per SXTP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946563), 60 Degrees Pharmaceuticals Inc. generated $1.0M in revenue (+65.5% YoY), -$7.4M in net income, and -$7.0M in free cash flow against $5.4M in total assets and $144.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.94 (-0.33%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SXTP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY SXTP SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 48.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.90+2.2% Next Q

Q2 (-2Q)

Grade E$0.92-19.6% Next Q

Q3 (-1Q)

Grade E$0.74+27% Next Q

Current

Grade D-$0.94-7.8% Hist 90D α

Trajectory: E (30) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SXTP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SXTP currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.00) and Max Pain ($0.99) forces dealer call-delta covering toward $9.05.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SXTP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SXTP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SXTP)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SXTP.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SXTP)

✓Walkthrough of SXTP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SXTP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.61%▼ DESCENDING CHANNEL

2026-11-03O $0.95H $0.95L $0.94C $0.94VOL 73.5K

RES: $1.58SUP: $0.55SMA50: $1.00SMA200: $1.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SXTP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SXTP Butterfly Map → + Track SXTP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +65.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SXTP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SXTP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SXTP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SXTP)

Health Care Rank #524 of 1016 ⚔️ ONCO vs SXTP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SXTP vs. ONCO, GRI, EOCN, ERNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, 60 Degrees Pharmaceuticals Inc. (SXTP) ranks #524 by composite RQD confidence (38/100, grade D-) and #971 by equity capitalization ($3.3M). Within this direct 5-issuer industry benchmark cohort, SXTP leads on earnings valuation at N/A trailing P/E, while SXTP leads on capital efficiency and profitability with -35.0% ROIC and 22.3% gross margin. SXTP currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SXTP ACTIVE 60 Degrees Pharmaceuticals Inc.	D-	38/100	—	22.3%	-35.0%	-0.79%	$3.3M	Benchmark Subject
ONCO Onconetix Inc.	E	30/100	—	77.6%	-35.0%	-4.27%	$3.3M	/onco-vs-sxtp →
GRI GRI Bio Inc.	E	34/100	—	—	-35.0%	-2.55%	$3.3M	/gri-vs-sxtp →
EOCN Eocene Ltd.	E	34/100	—	—	-35.0%	-3.73%	$3.2M	/eocn-vs-sxtp →
ERNA Ernexa Therapeutics Inc.	E	33/100	—	—	-35.0%	-6.63%	$3.2M	/erna-vs-sxtp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001946563

In its most recent audited fiscal period (FY2025, filed 2025-12-31), 60 Degrees Pharmaceuticals Inc. (SXTP) reported GAAP revenue of $1.0M (+65.5% vs. FY2024 revenue of $607.6K , and +296.5% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$6.8M, and free cash flow of -$7.0M (-21.5% YoY). On the balance sheet, SXTP closed FY2025 with $5.4M in total assets against $144.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.0M	-$7.4M	-$6.8M	-$7.0M	$5.4M	$144.0K
FY2024 (FY)	2024-12-31	$607.6K	-$7.9M	-$5.6M	-$5.8M	$5.8M	$147.1K
FY2023 (FY)	2023-12-31	$253.6K	-$3.8M	-$4.5M	-$4.5M	—	—

3. SXTP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SXTP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SXTP compare to ONCO and GRI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SXTP?

Where is SXTP trading relative to its 50-day, 200-day, and 52-week technical levels?

SXTP last traded at $0.94 (-0.79% on volume of 73,529 shares), positioning the stock -6.00% below its 50-day simple moving average ($1.00) and -46.59% below its 200-day simple moving average ($1.76). Across its 52-week range of $0.59 to $8.62, SXTP sits at the 4.4% percentile with a 14-day RSI of 48.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.06).

SXTP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SXTP's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SXTP.

Direct Sub-Reports: SXTP RQD Cockpit SXTP 12M Forecast SXTP Earnings & Move SXTP Dividends & DRIP SXTP Insiders & 13F SXTP Whale Options SXTP Profit Sankey SXTP News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SXTP — 60 Degrees Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:54:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SXTP scores 38 / 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 6 / 20 (ROIC -35%; FCF yield 0%). This is the weakest pillar and reflects negative returns on invested capital and no free-cash-flow yield.
Whale 13F Flow: 6 / 20 (institutional accumulation and options positioning). The rating reflects limited institutional support in the scored data.
Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the lowest pillar score and indicates weak insider signal support.
Macro Regime Fit: 10 / 20 (Beta 1.0; sector sensitivity). The beta of 1.0 places the stock in line with the broader market, with no defensive offset.
Forensic Balance Sheet: 11 / 20 (Altman Z 2.5; Piotroski F 5/9; Debt/Equity 0.04). This is the strongest pillar, supported by low reported leverage, though the Altman Z and Piotroski F readings are mid-range rather than strong.

For a prospective investor, the rating points to a company with negative operating economics and cash burn, where the principal support is a low debt load rather than earnings or cash generation. Upside drivers in the source data are limited to catalysts described in the news wire; valuation tradeoffs are severe, since the company is reported at a $3.3M market capitalization with a 52-week range of $0.59 - $8.62. The rating is analytical, not a recommendation.

Business

60 Degrees Pharmaceuticals Inc. (SXTP) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its specific products, customers, or revenue model. Reported revenue was $1.0M for FY 2025, per the SEC financials. Not available in source data for further detail on how the company earns revenue.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1.0M	$-7.8M	$-7.4M	N/A	$-7.0M	$1.5M	$0.1M
FY 2024	$0.6M	$-9.7M	$-7.9M	N/A	$-5.8M	$1.7M	$0.1M
FY 2023	$0.3M	$-5.2M	$-3.8M	N/A	$-4.5M	N/A	N/A

Per the SEC financials, revenue rose across the three reported periods while operating and net losses persisted in each year. Per the market data, the gross margin is 22.3%, the operating margin is -60%, the net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, with a Debt/Equity of 0.04. Reported debt is small relative to cash, though cash declined from $1.7M to $1.5M across FY 2024 to FY 2025 while free cash flow remained negative.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed (all items tagged to SXTP):

A headline references a January 2027 babesiosis data readout and planned FDA pre-sNDA meeting (flagged YELLOW, market wire).
A headline references the company and Exyn Technologies interviews airing on CNBC and Bloomberg TV (flagged YELLOW, market wire).
A headline reports the stock falling 6% pre-market ahead of tafenoquine trial interim results (flagged RED, risk watch).
A headline describes the stock whipsawing as traders study its financials (flagged YELLOW, market wire).
A headline notes a 30-patient trial remaining blinded as the company plans its next FDA meeting (flagged YELLOW, market wire).
A headline describes the stock grinding higher amid volatile price action (flagged YELLOW, market wire).

Per the Butterfly Supply-Chain Graph, the supply chain is marked NONE, with no butterfly links and no proprietary signals.

Open Questions

What specific products and indications does the company develop, and what stage is each in?
What is the cash runway given $1.5M in reported cash against FY 2025 free cash flow of $-7.0M?
What were the outcomes of the tafenoquine trial interim results referenced in the news feed?
Why are EPS, P/E, and EV/EBITDA not reported, and what share count underlies the $3.3M market capitalization?
What is the status and terms of the planned FDA pre-sNDA meeting?

SXTP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for 60 Degrees Pharmaceuticals Inc. (SXTP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SXTP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting

Yahoo Finance report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Knoxville News Sentinel • 19h ago

60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Knoxville News Sentinel report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TradingView • 22h ago

60 Degrees Pharmaceuticals Stock Falls 6% in Pre-Market Ahead of Tafenoquine Trial Interim Results: What Investors Are Watching Tuesday?

TradingView report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Timothy Sykes • 1d ago

SXTP Stock Whipsaws As Traders Study Deep Red Financials

Timothy Sykes report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A 30-patient trial remains blinded as 60 Degrees Pharma (SXTP) plans its next FDA meeting.

Stock Titan report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StocksToTrade • 1d ago

SXTP Stock Grinds Higher As Traders Track Volatile Price Action

StocksToTrade report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

All five patients reported improvement; a sensitive post-treatment test found no parasite in four.

Stock Titan report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 5d ago

60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome

Company plans to explore botanical approval pathways before initiating a prescription drug development programWASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Com

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SXTP Bull vs. Bear Conversation Board — What's Your Call at $0.94?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SXTP 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.84 (-11.6%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SXTP (D- • RQD 38/100) a Buy at $0.95?

Welcome to the SXTP (60 Degrees Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.78 (-17.9%)

Spot @ $0.95

Pump the brakes on SXTP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SXTP, but look at what you are paying: current EV/EBITDA multiples with 22.3% gross margins. Unless 60 Degrees Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.15 (+21.1%)

Spot @ $0.95

SXTP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SXTP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.95 (52-wk range $0.59 - $8.62), any beat on forward guidance forces shorts and underweight funds to chase.